Literature DB >> 26226199

Current Therapy of Acquired Ocular Toxoplasmosis: A Review.

Guilherme Sturzeneker Cerqueira Lima1, Patricia Grativol Costa Saraiva2, Fábio Petersen Saraiva1.   

Abstract

Caused by the parasite Toxoplasma gondii, ocular toxoplasmosis (OT) is the most common form of posterior infectious uveitis. Combined antiparasitic therapy is the standard treatment for OT, but several other schemes have been proposed. The purpose of the present study was to review the literature on the treatment of OT and provide ophthalmologists with up-to-date information to help reduce OT-related visual morbidity. In conclusion, no ideal treatment scheme was identified; currently prescribed therapeutic schemes yield statistically similar functional outcomes.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26226199     DOI： 10.1089/jop.2015.0059

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN： 1080-7683            Impact factor:   2.671


  6 in total

Review 1.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  The Role of Corticosteroids in Treating Acute Ocular Toxoplasmosis in an Immunocompetent Patient: A Case Report.

Authors:  Hung-Yi Lin; Wan-Ju Annabelle Lee
Journal:  Front Med (Lausanne)       Date:  2022-06-29

3.  Rapid resolution of toxoplasma chorioretinitis treatment using quadruple therapy.

Authors:  Arief Kartasasmita; Wendy P Muntur; Sutarya Enus; Erwin Iskandar
Journal:  Clin Ophthalmol       Date:  2017-12-01

4.  Toxoplasma gondii exposure and epilepsy: A matched case-control study in a public hospital in northern Mexico.

Authors:  Cosme Alvarado-Esquivel; Yazmin Del Rosario Rico-Almochantaf; Jesús Hernández-Tinoco; Gerardo Quiñones-Canales; Luis Francisco Sánchez-Anguiano; Jorge Torres-González; Eda Guadalupe Ramírez-Valles; Andrea Minjarez-Veloz
Journal:  SAGE Open Med       Date:  2018-04-10

5.  A prospective randomized trial of azithromycin versus trimethoprim/sulfamethoxazole in treatment of toxoplasmic retinochoroiditis.

Authors:  Alireza Lashay; Ahmad Mirshahi; Najaf Parandin; Hamid Riazi Esfahani; Mehdi Mazloumi; Mohammad Reza Lashay; Mohammad Karim Johari; Elham Ashrafi
Journal:  J Curr Ophthalmol       Date:  2016-12-28

6.  The P2X7 Receptor Mediates Toxoplasma gondii Control in Macrophages through Canonical NLRP3 Inflammasome Activation and Reactive Oxygen Species Production.

Authors:  Aline Cristina Abreu Moreira-Souza; Cássio Luiz Coutinho Almeida-da-Silva; Thuany Prado Rangel; Gabrielle da Costa Rocha; Maria Bellio; Dario Simões Zamboni; Rossiane Claudia Vommaro; Robson Coutinho-Silva
Journal:  Front Immunol       Date:  2017-10-12       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.